Kirby McInerney LLP | Whistleblower Practice | Featured Cases
This links to the home page
Featured Cases

  • Egon Zehnder Tax Whistleblower Case

    State of NY ex rel. American Advisory Services LLC v. Egon Zehnder International, Inc., No. 100115/2017. Filed on January 30, 2017, unsealed on July 21, 2021.

  • Sandell Hedge Fund Tax Whistleblower Settlement

    State of NY ex rel. Tooley, LLC v. Sandell, et al., No. 101494/2018. Whistleblower client received award of 21% of $105 million recovery.

  • FPR Specialty Pharmacy

    United States ex rel. Doe v. FPR Specialty Pharmacy LLC, No. 16-cv-5204 (SDNY). Whistleblower client received 21% of $426,000 ability to pay settlement

  • Moody’s Corporation Whistleblower Settlement

    State of New York ex rel. Banerjee v. Moody’s Corporation, No. 103997/2012 (N.Y. Sup. Ct. 2019). Whistleblower client received award of 30% of $8.5 million recovery.

  • JPMorgan Chase Escheatment

    New York ex rel. Raw Data Analytics v. JPMorgan Chase & Co., No. 100271/2015 (N.Y. Sup. Ct.). Defeated defendants' summary judgment motion, and case continues.

  • Spa Castle Whistleblower Settlement

    State of New York ex rel. Choe v. Spa Castle, Inc., No. 101243/2014 (N.Y. Sup. Ct. 2018). Whistleblower client received award of 23% of $2.5 million recovery.

  • Winds Enterprises Whistleblower Settlement

    U.S. ex rel. Dickhudt v. Winds Enterprises, No. 13-cv-01142 (W.D. Wa.). Whistleblower client received award of 20% of $1.5 million settlement.

  • Noble Jewelry Whistleblower Settlement

    U.S. ex rel. Karlin v. Noble Jewelry Co., No. 08-cv-07826 (S.D.N.Y.). Whistleblower client received award of 19% of $3.85 million settlement.

  • Multi-Defendant Prescription Drug Pricing Settlement

    In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456 (D. Mass.); City of New York, et al. v. Abbott Laboratories, et al., No. 01-cv-12257 (D. Mass). Represented New York City in False Claims Act case against several prescription drug manufacturers for manipulating Average Wholesale Prices of their drugs, settling for $225 million.